Anixa Biosciences (ANIX) Common Equity (2010 - 2026)
Anixa Biosciences (ANIX) recorded Common Equity of $14.47 million in fiscal Q3 2026 (quarter ended Jul 31, 2026), down 6.1% from $15.41 million a year earlier but up 9.4% from the prior quarter.
Powered by 
Analysis
Anixa Biosciences (ANIX) Common Equity (2010 - 2026) Analysis & Trends
At the end of FY2025 (ended Oct 31, 2025), Anixa Biosciences reported Common Equity of $15.16 million, down 19.7% from FY2024.
- Annual Common Equity has declined for four straight fiscal years, though with a five-year compound annual growth rate of 12.9% (FY2020 to FY2025).
- Across earlier fiscal years, Common Equity came in at $18.89 million in FY2024 (-19.2%), $23.37 million in FY2023 (-17.1%), $28.2 million in FY2022 (-18.9%) and $34.77 million in FY2021 (+320.7%).
- Quarterly Common Equity has ranged from $13.22 million in fiscal Q2 2026 to $34.77 million in fiscal Q4 2021 over the past five years.
- Peak year-over-year performance for Common Equity in the last five years was growth of 320.7% in fiscal Q4 2021, against a decline of 34.0% in fiscal Q2 2025 at the low end.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,230.11 Bn | 1,198.70 Bn | 19.71 Bn | 33.88 Bn |
| 2 | Johnson & Johnson | 644.39 Bn | 564.25 Bn | 17.30 Bn | 81.53 Bn |
| 3 | AbbVie | 503.52 Bn | 476.68 Bn | 12.70 Bn | -5.94 Bn |
| 4 | Merck | 363.29 Bn | 317.72 Bn | 12.21 Bn | 41.98 Bn |
| 5 | Novartis Ag | 298.23 Bn | 262.62 Bn | 11.24 Bn | 41.95 Bn |
| 6 | Astrazeneca | 267.53 Bn | 241.29 Bn | 12.86 Bn | 50.37 Bn |
| 7 | Amgen | 241.80 Bn | 197.20 Bn | 7.24 Bn | 11.69 Bn |
| 8 | Gilead Sciences | 195.07 Bn | 169.19 Bn | 6.22 Bn | 11.83 Bn |
| 9 | Pfizer | 173.33 Bn | 120.28 Bn | 10.94 Bn | 85.49 Bn |
| 10 | Anixa Biosciences | 96.15 Mn | 81.01 Mn | - | 14.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 31, 2026 | 14.47 Mn |
| Apr 30, 2026 | 13.22 Mn |
| Oct 31, 2025 | 15.16 Mn |
| Jul 31, 2025 | 15.41 Mn |
| Apr 30, 2025 | 14.91 Mn |
| Jan 31, 2025 | 16.71 Mn |
| Oct 31, 2024 | 18.89 Mn |
| Jul 31, 2024 | 20.69 Mn |
| Apr 30, 2024 | 22.58 Mn |
| Jan 31, 2024 | 23.60 Mn |
| Oct 31, 2023 | 23.37 Mn |
| Jul 31, 2023 | 24.59 Mn |
| Apr 30, 2023 | 25.91 Mn |
| Jan 31, 2023 | 26.91 Mn |
| Oct 31, 2022 | 28.20 Mn |
| Jul 31, 2022 | 30.91 Mn |
| Apr 30, 2022 | 31.41 Mn |
| Jan 31, 2022 | 33.24 Mn |
| Oct 31, 2021 | 34.77 Mn |
| Jul 31, 2021 | 35.85 Mn |
API Access
Anixa Biosciences Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=ANIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "ANIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=ANIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();